2-Amino_6MP

Category

2-Amino_6MP




Useful info

2-Amino_6MP Brand names, 2-Amino_6MP Analogs

2-Amino_6MP Brand Names Mixture

  • No information avaliable

    • 2-Amino_6MP Chemical_Formula

    C5H5N5S

    2-Amino_6MP RX_link

    http://www.rxlist.com/cgi/generic2/thioguanine.htm

    2-Amino_6MP fda sheet

    2-Amino_6MP FDA

    2-Amino_6MP msds (material safety sheet)

    2-Amino_6MP MSDS

    2-Amino_6MP Synthesis Reference

    Elion et al.; J.Amer.Chem.Soc.; 81;1898,1901 (1959)

    2-Amino_6MP Molecular Weight

    167.193 g/mol

    2-Amino_6MP Melting Point

    >360 oC

    2-Amino_6MP H2O Solubility

    36.3 mg/mL

    2-Amino_6MP State

    Solid

    2-Amino_6MP LogP

    0.086

    2-Amino_6MP Dosage Forms

    Oral tablets

    2-Amino_6MP Indication

    For remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.

    2-Amino_6MP Pharmacology

    Thioguanine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute nonlymphocytic leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Thioguanine was first synthesized and entered into clinical trial more than 30 years ago. It is a 6-thiopurine analogue of the naturally occurring purine bases hypoxanthine and guanine. Intracellular activation results in incorporation into DNA as a false purine base. An additional cytotoxic effect is related to its incorporation into RNA. Thioguanine is cross-resistant with mercaptopurine. Cytotoxicity is cell cycle phase-specific (S-phase).

    2-Amino_6MP Absorption

    Absorption of an oral dose is incomplete and variable, averaging approximately 30% of the administered dose (range: 14% to 46%)

    2-Amino_6MP Toxicity

    Oral, mouse: LD50 = 160 mg/kg. Symptoms of overdose include nausea, vomiting, malaise, hypotension, and diaphoresis.

    2-Amino_6MP Patient Information

    PATIENT INFORMATION

    Patients should be informed that the major toxicities of thioguanine are related to
    myelosuppression, hepatotoxicity, and gastrointestinal toxicity. Patients should never
    be allowed to take the drug without medical supervision and should be advised to consult
    their physician if they experience fever, sore throat, jaundice, nausea, vomiting, signs
    of local infection, bleeding from any site, or symptoms suggestive of anemia. Women of
    childbearing potential should be advised to avoid becoming pregnant.

    2-Amino_6MP Organisms Affected

    Humans and other mammals